128 related articles for article (PubMed ID: 3283767)
1. Chemotherapy for metastatic bladder cancer; the EORTC experience.
Stoter G
Prog Clin Biol Res; 1988; 260():471-9. PubMed ID: 3283767
[No Abstract] [Full Text] [Related]
2. Chemotherapy for advanced urothelial cancer.
Yagoda A
Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
[No Abstract] [Full Text] [Related]
3. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
[No Abstract] [Full Text] [Related]
4. [MEC treatment (methotrexate, etoposide, cisplatin) for urothelial cancer].
Miura T; Murai T; Shimura H; Kondo I
Gan To Kagaku Ryoho; 1992 May; 19(5):731-3. PubMed ID: 1580650
[No Abstract] [Full Text] [Related]
5. Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Bosl G; Watson RC; Hollander PS
Prog Clin Biol Res; 1988; 260():551-5. PubMed ID: 3283770
[No Abstract] [Full Text] [Related]
6. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
Walther PJ
Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
[No Abstract] [Full Text] [Related]
7. Adjuvant chemotherapy for non-organ confined bladder transitional cell carcinoma.
Abi-Aad AS
Acta Urol Belg; 1996 May; 64(2):35-7. PubMed ID: 8701808
[No Abstract] [Full Text] [Related]
8. The cisplatin-methotrexate neo-adjuvant protocol as first-line therapy of bladder cancer. Present experience in Palermo.
Ingargiola GB; Lamartina M; Cassata G; Corselli G; Serretta V; Caramia G; Rizzo FP; Pavone-Maculuso M
Prog Clin Biol Res; 1988; 260():579-83. PubMed ID: 3362907
[No Abstract] [Full Text] [Related]
9. Neoadjuvant chemotherapy in T3-4 N0-X M0 transitional cell carcinoma of the bladder. Problems of clinical and pathological evaluation of response.
Splinter TA; ten Kate FJ; Schröder FH; Denis L; Newling D; Jones WG; Jacqmin D; Boeken Kruger CG; Stoter G; de Voogt HJ
Prog Clin Biol Res; 1988; 269():579-90. PubMed ID: 3393555
[No Abstract] [Full Text] [Related]
10. Preoperative chemotherapy in T3-T4 Nx Mo bladder cancer with cisplatinum and methotrexate.
Denis L; Da Silva FC; Hendrickx L
Prog Clin Biol Res; 1988; 260():571-7. PubMed ID: 3362906
[No Abstract] [Full Text] [Related]
11. Overview of bladder cancer trials in the European Organization for Research and Treatment.
de Wit R;
Cancer; 2003 Apr; 97(8 Suppl):2120-6. PubMed ID: 12673705
[TBL] [Abstract][Full Text] [Related]
12. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of metastatic bladder cancer.
Yagoda A
Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
[No Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
16. [Systemic chemotherapy in advanced bladder cancer. New aspects].
Jakse G
Wien Klin Wochenschr; 1987 Jan; 99(2):54-7. PubMed ID: 3564487
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of neoadjuvant intraarterial chemotherapy (I A-MAC) for advanced bladder cancer].
Takahashi Y; Deguchi T; Kuriyama M; Nakano M; Ueno K; Shinoda I; Takeda A; Itoh S; Doi T; Takeuchi T
Gan To Kagaku Ryoho; 1994 Sep; 21(13):2311-4. PubMed ID: 7944467
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for advanced urothelial cancer patients with a combination of low-dose consecutive cisplatin and etoposide].
Hashimoto H; Tokumitsu M; Morikawa M; Numata A; Yachiku S; Iuchi H; Yamauchi K
Gan To Kagaku Ryoho; 1996 Jun; 23(7):941-4. PubMed ID: 8678548
[No Abstract] [Full Text] [Related]
20. [Effect of combination chemotherapy of tegafur, adriamycin and cisplatin on patients with advanced relapsing prostatic carcinoma and advanced bladder tumor].
Yoshida K; Nakame Y; Horiuchi S; Kaneoya F; Kuroda T; Tanoiri A; Koizumi M; Takahashi M; Negishi T; Saitoh H
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1083-5. PubMed ID: 3083786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
